An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial

BACKGROUND: This study focuses on genetically stratified subgroups of Parkinson’s disease patients (PD) with an enrichment of risk variants in mitochondrial genes,who might benefit from treatment with the “mitochondrial enhancer” coenzyme Q10 (156 mg coenzyme Q10/d [QuinoMit Q10® Fluid] over six mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasuhn, Jannik, Brüggemann, Norbert, Hessler, Nicole, Berg, Daniela, Gasser, Thomas, Brockmann, Kathrin, Olbrich, Denise, Ziegler, Andreas, König, Inke R., Klein, Christine, Kasten, Meike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650116/
https://www.ncbi.nlm.nih.gov/pubmed/33324897
http://dx.doi.org/10.1186/s42466-019-0033-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650116/
https://www.ncbi.nlm.nih.gov/pubmed/33324897
http://dx.doi.org/10.1186/s42466-019-0033-1

Ejemplares similares